SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $4,592,076,814 |
| Positions | 41 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $899,060,606 | 7,679,684 |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $613,032,889 | 18,088,902 |
| ERASCA INC | ERAS | COM | $457,545,444 | 24,975,188 |
| MBX BIOSCIENCES INC | MBX | COM | $367,191,118 | 6,652,013 |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | COM | $258,909,678 | 9,874,511 |
| TREVI THERAPEUTICS INC | TRVI | COM | $185,370,687 | 9,939,447 |
| KRYSTAL BIOTECH INC | KRYS | COM | $178,887,373 | 481,307 |
| MAZE THERAPEUTICS INC | MAZE | COM | $150,182,184 | 5,032,915 |
| PHATHOM PHARMACEUTICALS INC | PHAT | COM | $135,261,406 | 12,466,489 |
| PALVELLA THERAPEUTICS INC NE | PVLA | COM | $134,848,368 | 882,400 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.